The efficacy of early immunosuppression in a morphea patient complicated with pulmonary interstitial fibrosis.

08:00 EDT 14th August 2019 | BioPortfolio

Summary of "The efficacy of early immunosuppression in a morphea patient complicated with pulmonary interstitial fibrosis."

No Summary Available


Journal Details

This article was published in the following journal.

Name: Dermatologic therapy
ISSN: 1529-8019
Pages: e13061


DeepDyve research library

PubMed Articles [22697 Associated PubMed Articles listed on BioPortfolio]

Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort.

Prospective, longitudinal studies examining the features of linear morphea are limited.

Morphea induced by treatment with Interferon β-1α.

The etiology of morphea is poorly understood, but small vessel endothelial damage, T-cell recruitment, immune dysregulation, and the release of profibrotic cytokines likely contribute to pathogenesis....

Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery.

The phosphodiesterase-5 inhibitor sildenafil was developed for the treatment of pulmonary hypertension. The authors investigated the efficacy and safety of sildenafil in the early postoperative period...

Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphea by severity and identify clinically significant change.

Validated scoring measures in morphea can facilitate clinical trials.

Treatment of Morphea With Hydroxychloroquine: A Retrospective Review of 84 Patients at Mayo Clinic, 1996-2013.

Few studies support treating morphea (localized scleroderma) with hydroxychloroquine.

Clinical Trials [12811 Associated Clinical Trials listed on BioPortfolio]

Study to Assess Sarilumab in Halting Progression of Morphea

An open-label single center trial studying the efficacy and safety of sarilumab on morphea patients.

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.

Molecular Effects of Topical Calcipotriene on Morphea

This study will look into how topical treatment with synthetic Vitamin D3, calcipotriene ointment, used as standard of care, works in patients with morphea. Skin biopsies of morphea lesion...

Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study

Localized scleroderma or morphea is a fibrotic disease, imiquimod induces cytokines which inhibit fibrotic activity . We propose that topical imiquimod 5% cream is efficacious and safe in ...

Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea

This is a study designed to evaluate the comparative effectiveness of topical medications for the treatment of circumscribed morphea.

Medical and Biotech [MESH] Definitions

Hypertrophy and dilation of the RIGHT VENTRICLE of the heart that is caused by PULMONARY HYPERTENSION. This condition is often associated with pulmonary parenchymal or vascular diseases, such as CHRONIC OBSTRUCTIVE PULMONARY DISEASE and PULMONARY EMBOLISM.

Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.

A syndrome of persistent PULMONARY HYPERTENSION in the newborn infant (INFANT, NEWBORN) without demonstrable HEART DISEASES. This neonatal condition can be caused by severe pulmonary vasoconstriction (reactive type), hypertrophy of pulmonary arterial muscle (hypertrophic type), or abnormally developed pulmonary arterioles (hypoplastic type). The newborn patient exhibits CYANOSIS and ACIDOSIS due to the persistence of fetal circulatory pattern of right-to-left shunting of blood through a patent ductus arteriosus (DUCTUS ARTERIOSUS, PATENT) and at times a patent foramen ovale (FORAMEN OVALE, PATENT).

The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.

Narrowing below the PULMONARY VALVE or well below it in the infundibuluar chamber where the pulmonary artery originates, usually caused by a defective VENTRICULAR SEPTUM or presence of fibrous tissues. It is characterized by restricted blood outflow from the RIGHT VENTRICLE into the PULMONARY ARTERY, exertional fatigue, DYSPNEA, and chest discomfort.

Quick Search

DeepDyve research library

Relevant Topic

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Searches Linking to this Article